137 related articles for article (PubMed ID: 33783376)
1. eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma.
Fang C; Xie H; Zhao J; Wang W; Hou H; Zhang B; Zhou D; Geng X
Anticancer Drugs; 2021 Sep; 32(8):822-828. PubMed ID: 33783376
[TBL] [Abstract][Full Text] [Related]
2. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
3. Modulation of 4E-BP1 function as a critical determinant of enzastaurin-induced apoptosis.
Dumstorf CA; Konicek BW; McNulty AM; Parsons SH; Furic L; Sonenberg N; Graff JR
Mol Cancer Ther; 2010 Dec; 9(12):3158-63. PubMed ID: 20971826
[TBL] [Abstract][Full Text] [Related]
4. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Fan S; Li Y; Yue P; Khuri FR; Sun SY
Neoplasia; 2010 Apr; 12(4):346-56. PubMed ID: 20360945
[TBL] [Abstract][Full Text] [Related]
5. eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Boussemart L; Malka-Mahieu H; Girault I; Allard D; Hemmingsson O; Tomasic G; Thomas M; Basmadjian C; Ribeiro N; Thuaud F; Mateus C; Routier E; Kamsu-Kom N; Agoussi S; Eggermont AM; Désaubry L; Robert C; Vagner S
Nature; 2014 Sep; 513(7516):105-9. PubMed ID: 25079330
[TBL] [Abstract][Full Text] [Related]
6. Meal feeding enhances formation of eIF4F in skeletal muscle: role of increased eIF4E availability and eIF4G phosphorylation.
Vary TC; Lynch CJ
Am J Physiol Endocrinol Metab; 2006 Apr; 290(4):E631-42. PubMed ID: 16263769
[TBL] [Abstract][Full Text] [Related]
7. Mitosis-related phosphorylation of the eukaryotic translation suppressor 4E-BP1 and its interaction with eukaryotic translation initiation factor 4E (eIF4E).
Sun R; Cheng E; Velásquez C; Chang Y; Moore PS
J Biol Chem; 2019 Aug; 294(31):11840-11852. PubMed ID: 31201269
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism of the dual activity of 4EGI-1: Dissociating eIF4G from eIF4E but stabilizing the binding of unphosphorylated 4E-BP1.
Sekiyama N; Arthanari H; Papadopoulos E; Rodriguez-Mias RA; Wagner G; Léger-Abraham M
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4036-45. PubMed ID: 26170285
[TBL] [Abstract][Full Text] [Related]
9. IGF-I and insulin regulate eIF4F formation by different mechanisms in muscle and liver in the ovine fetus.
Shen W; Mallon D; Boyle DW; Liechty EA
Am J Physiol Endocrinol Metab; 2002 Sep; 283(3):E593-603. PubMed ID: 12169454
[TBL] [Abstract][Full Text] [Related]
10. Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.
Connor JH; Lyles DS
J Virol; 2002 Oct; 76(20):10177-87. PubMed ID: 12239292
[TBL] [Abstract][Full Text] [Related]
11. Cellular stress in xenopus kidney cells enhances the phosphorylation of eukaryotic translation initiation factor (eIF)4E and the association of eIF4F with poly(A)-binding protein.
Fraser CS; Pain VM; Morley SJ
Biochem J; 1999 Sep; 342 Pt 3(Pt 3):519-26. PubMed ID: 10477262
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.
George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH
J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107
[TBL] [Abstract][Full Text] [Related]
13. 4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
De A; Jacobson BA; Peterson MS; Jay-Dixon J; Kratzke MG; Sadiq AA; Patel MR; Kratzke RA
Invest New Drugs; 2018 Apr; 36(2):217-229. PubMed ID: 29116477
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G.
Moerke NJ; Aktas H; Chen H; Cantel S; Reibarkh MY; Fahmy A; Gross JD; Degterev A; Yuan J; Chorev M; Halperin JA; Wagner G
Cell; 2007 Jan; 128(2):257-67. PubMed ID: 17254965
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin limits formation of active eukaryotic initiation factor 4F complex following meal feeding in rat hearts.
Vary TC; Deiter G; Lynch CJ
J Nutr; 2007 Aug; 137(8):1857-62. PubMed ID: 17634255
[TBL] [Abstract][Full Text] [Related]
16. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
17. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of bromophenol-thiazolylhydrazone hybrids inhibiting the interaction of translation initiation factors eIF4E/eIF4G as multifunctional agents for cancer treatment.
Wang L; Guo C; Li X; Yu X; Li X; Xu K; Jiang B; Jia X; Li C; Shi D
Eur J Med Chem; 2019 Sep; 177():153-170. PubMed ID: 31132531
[TBL] [Abstract][Full Text] [Related]
19. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
Jacobson BA; Thumma SC; Jay-Dixon J; Patel MR; Dubear Kroening K; Kratzke MG; Etchison RG; Konicek BW; Graff JR; Kratzke RA
PLoS One; 2013; 8(11):e81669. PubMed ID: 24260583
[TBL] [Abstract][Full Text] [Related]
20. 5'-Cap‒Dependent Translation as a Potent Therapeutic Target for Lethal Human Squamous Cell Carcinoma.
Srivastava RK; Khan J; Arumugam A; Muzaffar S; Guroji P; Gorbatyuk MS; Elmets CA; Slominski AT; Mukhtar MS; Athar M
J Invest Dermatol; 2021 Apr; 141(4):742-753.e10. PubMed ID: 32971126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
